Immunomedics Inc. (IMMU)

16.75
0.53 3.30
NASDAQ : Health Technology
Prev Close 16.22
Open 16.32
Day Low/High 16.23 / 16.83
52 Wk Low/High 4.73 / 18.93
Volume 195.27K
Avg Volume 2.98M
Exchange NASDAQ
Shares Outstanding 165.78M
Market Cap 2.73B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

The Newark, Calif.-based firm unveiled positive top-line results from a pair of studies evaluating RT002 for the treatment of glabellar, or frown, lines.

Interesting IMMU Put And Call Options For December 15th

Interesting IMMU Put And Call Options For December 15th

Investors in Immunomedics, Inc. saw new options become available this week, for the December 15th expiration.

Short Interest Declines 14% For IMMU

Short Interest Declines 14% For IMMU

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 4,840,764 share decrease in total short interest for Immunomedics, Inc. , to 29,775,931, a decrease of 13.98% since 09/15/2017.

Kite Takeover by Gilead Lifts Biotech Stocks

Kite Takeover by Gilead Lifts Biotech Stocks

The key to dealing with this environment is to keep an open mind.

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer

Results Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology

Immunomedics Announces Results Of Special Stockholder Meeting

Immunomedics Announces Results Of Special Stockholder Meeting

Obtains stockholder approval to increase authorized capital stock

Commit To Purchase Immunomedics At $4, Earn 12.5% Using Options

Investors eyeing a purchase of Immunomedics, Inc. shares, but tentative about paying the going market price of $7.64/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Biotech Movers: Immunomedics, Aerie, Exelixis

Biotech Movers: Immunomedics, Aerie, Exelixis

Immunomedics, Aerie Pharmaceuticals and Exelixis were among the biotech movers in premarket trading on Friday.

Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments

Closes on $125 million private placement financing with institutional investors

TheStreet Quant Rating: C- (Hold)